Affibody Medical Investor Relations
Categories:
Navigation:
Non-Regulatory
May 19, 2015
Interim Report – January to March 2015
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™,...
Read more
February 27, 2015
Year End Report 2014
November 27, 2014
Nordic Nanovector and Affibody collaborate on advanced radio-immunotherapies program for Multiple Myeloma
Oslo, Norway and Solna, Sweden – Nordic Nanovector ASA and Affibody AB today announced that the companies have entered into a three-year collaborative research agreement to discover and develop...
November 20, 2014
Interim Report – January to September 2014
August 22, 2014
Interim Report – January to June 2014
Affibody Medical AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its...
May 20, 2014
Interim Report – January to March 2014
April 28, 2014
First Patient Included in PET Imaging Study of HER2 Expression in Breast Cancer
Solna, Sweden, April 28, 2014. Affibody is pleased to announce that the first patient has been enrolled in a clinical study to evaluate ABY-025 for PET imaging of HER2...
April 8, 2014
Kallelse till årsstämma
Aktieägarna i Affibody Medical AB (publ) kallas härmed till årsstämma torsdagen den 8 maj 2014 kl 13.30 i bolagets lokaler, Gunnar Asplunds allé 24, Solna.
February 20, 2014
Year End Report 2013
